MedTrace Logo

Supervised Asthma Medication in Schools (SAMS)

NCT01997463 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 442

Last updated 2022-03-23

Study results available
· View outcomes & findings →

Summary

The investigators hypothesize that school-based, direct supervision of daily controller therapy will result in more effective asthma control, as assessed by the Asthma Control Questionnaire than usual care. Additionally, as the result of enhanced asthma control and resulting decrease in health care utilization, school-based, direct supervision of daily controller therapy will result in lower cost per quality-adjusted life year (QALY) gained than usual care.

Conditions

  • Childhood Asthma

Interventions

DRUG

Supervised asthma therapy in schools

Therapy observed daily in school. Asthma education by American Lung Association

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • University of Arizona

    lead OTHER

Principal Investigators

  • Lynn B Gerald, Ph.D., MSPH · University of Arizona, Mel and Enid Zuckerman College of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01997463 on ClinicalTrials.gov